Your browser doesn't support javascript.
loading
Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry.
Laurino, Mercy Y; Truitt, Anjali R; Tenney, Lederle; Fisher, Douglass; Lindor, Noralane M; Veenstra, David; Jarvik, Gail P; Newcomb, Polly A; Fullerton, Stephanie M.
Afiliación
  • Laurino MY; Cancer Prevention Program, Seattle Cancer Care Alliance, Seattle, Washington, USA.
  • Truitt AR; Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA.
  • Tenney L; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Fisher D; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Lindor NM; Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA.
  • Veenstra D; Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, USA.
  • Jarvik GP; Division of Medical Genetics, Department of Genome Sciences, University of Washington, Seattle, Washington, USA.
  • Newcomb PA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Fullerton SM; Department of Bioethics and Humanities, University of Washington, Seattle, Washington, USA.
Mol Genet Genomic Med ; 5(6): 700-708, 2017 11.
Article en En | MEDLINE | ID: mdl-29178651
BACKGROUND: The extent to which participants act to clinically verify research results is largely unknown. This study examined whether participants who received Lynch syndrome (LS)-related findings pursued researchers' recommendation to clinically verify results with testing performed by a CLIA-certified laboratory. METHODS: The Fred Hutchinson Cancer Research Center site of the multinational Colon Cancer Family Registry offered non-CLIA individual genetic research results to select registry participants (cases and their enrolled relatives) from 2011 to 2013. Participants who elected to receive results were counseled on the importance of verifying results at a CLIA-certified laboratory. Twenty-six (76.5%) of the 34 participants who received genetic results completed 2- and 12-month postdisclosure surveys; 42.3% of these (11/26) participated in a semistructured follow-up interview. RESULTS: Within 12 months of result disclosure, only 4 (15.4%) of 26 participants reported having verified their results in a CLIA-certified laboratory; of these four cases, all research and clinical results were concordant. Reasons for pursuing clinical verification included acting on the recommendation of the research team and informing future clinical care. Those who did not verify results cited lack of insurance coverage and limited perceived personal benefit of clinical verification as reasons for inaction. CONCLUSION: These findings suggest researchers will need to address barriers to seeking clinical verification in order to ensure that the intended benefits of returning genetic research results are realized.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Hereditarias sin Poliposis / Pruebas Genéticas Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Mol Genet Genomic Med Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Hereditarias sin Poliposis / Pruebas Genéticas Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Mol Genet Genomic Med Año: 2017 Tipo del documento: Article